ArticleMethods in molecular biology (Clifton, N.J.)2026
Ubiquitous and Brain Cell-Type-Specific Promoters and Enhancers in Lentiviral Vectors.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter discusses the development and application of constitutive and brain cell-type-specific promoters and enhancers in lentiviral vectors to enable precise and efficient gene delivery. The fundamental mechanisms of transcriptional regulation by promoters, distinguished between constitutive and cell-type-specific promoters, are outlined and the role of enhancers in modulating transcriptional activity is emphasized. Recent breakthroughs in single-cell transcriptomics and assay for transposase-accessible chromatin (ATAC) sequencing have led to the identification of novel enhancer regions, thus paving the way for the development of more refined and targeted lentiviral vectors. These advances have the potential to significantly improve the specificity and efficacy of transgene expression in distinct brain cell populations, including excitatory and inhibitory neurons, astrocytes, and microglia.
Indexed as
Identifiers
41273642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.